Fosun Diagnostics

What Fosun Diagnostics does

Fosun Diagnostics (复星诊断科技（上海）有限公司) is a China-based in vitro diagnostics (IVD) company operating as a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (复星医药, SHA: 600196), founded in 1994 with operational roots tracing to 1989. The company delivers a full IVD value chain from key raw materials to reagents to instruments, organized around six product segments: biochemistry, chemiluminescence immunoassay, molecular diagnostics (PCR), microbiology, colloidal gold / POCT chronic disease management, and pathology immunohistochemistry. Core instrument platforms include the F-i3000, F-i6000, and F-i1000 chemiluminescence analyzers (240-600 tests/hour per module, scalable to 3,600 tests/hour), the F-C2000 and F-C800 biochemical analyzers (up to 10,400 tests/hour), the F-A7000 laboratory automation system, and the F-AutoFlex96 nucleic acid extractor. Specialty reagent kits include ultra-sensitive viral hepatitis PCR (HBV DNA 5 IU/mL, HCV RNA 15 IU/mL), the I-SPOT.TB tuberculosis ELISPOT kit, NG-Test CARBA5 carbapenemase detection, Cytokine 14-item panel with exclusive GM-CSF and IL-15, and the MyCare antipsychotic blood concentration monitoring series (exclusive US partnership with Saladax). The company also markets the first-in-China NMPA-approved COVID-19/Influenza A&B triple antigen home self-test kit.

The company operates six specialized R&D and production bases across Shanghai (headquarters, Baoshan), Changsha (POCT), Taizhou (reagents), Hefei (immuno instruments), Suzhou (pathology), and Shenzhen (instrument R&D and international marketing). Fosun Diagnostics holds 800+ NMPA medical device registrations, 120+ CE/FDA overseas certifications, and 170+ valid authorized patents. The business model combines B2B enterprise field sales targeting Grade 2+ hospitals, maternal and child health hospitals, specialty hospitals, third-party independent laboratories, and primary care institutions with consumer distribution through pharmacies and e-commerce (Fengyouhui, Youzan) for home self-test kits. Revenue streams span instrument sales, recurring reagent and consumable revenue tied to the installed base, and after-sales service contracts, with strategic interoperability partnerships including Siemens Healthcare's FX Biochemical Immune Assembly Line combining the F-i3000 with the ADVIA Chemistry XPT. International reach covers 34 countries, and the company has a dedicated customer service hotline (400-619-6063) with 5-minute response, 2-hour solution, and 24-hour on-site service SLAs. In 2021 the company consolidated predecessor entities (Fosun Long March, Fosun Med-Tech, Changsha Zhongsheng Zhongjie, Jiangsu Changxing, Hefei Yuntao, Suzhou Abcarta) under the unified Fosun Diagnostics brand.

Name

Fosun Diagnostics

Legal name

复星诊断科技（上海）有限公司

Website

https://fosundiagnostics.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1–10 employees

Short description

Fosun Diagnostics is a Chinese in vitro diagnostics company and wholly-owned subsidiary of Fosun Pharma, providing a full IVD value chain across biochemistry, immunoassay, molecular diagnostics, microbiology, POCT, and pathology to hospitals, third-party labs, and home consumers in China and 34 international markets.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD)

akta.pro primary industry

Clinical Chemistry & Immunoassay Systems (HLAHAAAA)

akta.pro secondary industries

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

Keywords

• In vitro diagnostics
• Chemiluminescence immunoassay
• Clinical biochemistry analyzers
• Molecular diagnostic reagents
• Laboratory automation systems

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel

Revenue model

1. IVD Instruments and Analyzers: Sale of automated biochemical analyzers, chemiluminescence immunoassay analyzers, nucleic acid extractors, and other diagnostic instruments to hospitals and laboratories.
2. Diagnostic Reagents and Consumables: Sale of reagents for biochemistry, immunology, molecular diagnostics, microbiology, and POCT testing. Ongoing consumable revenue tied to instrument installed base.
3. After-sales Service: Comprehensive after-sales service including equipment installation, commissioning, calibration, repair, maintenance, reagent adjustment, performance verification, and user training.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

Fosun Diagnostics develops, manufactures, and sells a comprehensive range of in vitro diagnostics (IVD) products covering biochemistry, chemiluminescence immunoassay, molecular diagnostics (PCR), microbiology, POCT, and pathology. The product portfolio spans automated analyzers (F-i3000, F-i6000, F-C2000, F-AutoFlex96), diagnostic reagents and consumables, laboratory automation systems, and specialty kits for infectious disease, hepatitis, tuberculosis, and antipsychotic drug monitoring, sold to hospitals, clinical laboratories, and consumers.

Product overview

Fosun Diagnostics is a comprehensive in vitro diagnostics (IVD) company offering integrated solutions across six major product segments: Biochemistry, Immunoassays, Molecular Diagnostics, Microbiology, POCT (Point-of-Care Testing) for Chronic Disease Management, and Pathology. The company's product architecture follows a 'key raw materials + reagents + instruments' full industry chain model. Core offerings include automated chemiluminescence immunoassay analyzers (F-i6000, F-i3000, F-i1000) and biochemical analyzers (F-C2000, F-C800p/F-C800M) that can be combined into integrated biochemical-immune assembly lines (F-Ci6200, F-Ci3800) or connected to the F-A7000 series laboratory automation system. The molecular diagnostics portfolio includes nucleic acid extraction instruments (F-AutoFlex96), PCR systems, and comprehensive solutions for viral hepatitis, respiratory infections (COVID-19/Influenza A/B), and sexually transmitted diseases. Microbiology solutions feature the Droplet 48 automated susceptibility analyzer and NG-Test CARBA5 carbapenemase detection kit. POCT products include the GULP-1 'Four High' multi-parameter monitor and Relif series blood glucose meters. Pathology services are provided through the Suzhou Abcarta subsidiary. Specialty offerings include the I-SPOT.TB tuberculosis detection kit, MyCare blood drug concentration monitoring products, and the Cytokine 14-Item Detection Panel featuring exclusive GM-CSF and specialty IL-15 assays. The company operates six R&D and production bases across Shanghai (headquarters), Changsha, Taizhou, Hefei, and Shenzhen/Suzhou.

Differentiator

Problem solved

Functional benefit

Brands

• MyCare: Blood concentration monitoring product line for antipsychotic drugs (clozapine, olanzapine, quetiapine, aripiprazole, risperidone), co-developed with US-based Saladax. Used for therapeutic drug monitoring to guide personalized dosing.
• 星易检
• I-SPOT.TB
• GULP-1

Products and services

• Biochemistry Product Line
• Immunoassay Product Line
• Molecular Diagnostics Product Line
• Microbiology Product Line
• POCT Chronic Disease Management
• Pathology Product Line
• F-i6000 Automated Chemiluminescence Immunoassay Analyzer
• F-C2000 Automated Biochemical Analyzer
• F-Ci6200 Fully Automated Biochemical Immunoassay Integrated System
• F-i3000 Automated Chemiluminescence Immunoassay Analyzer
• F-A7000 Series Laboratory Automation System
• F-AutoFlex96 Nucleic Acid Extractor
• F-MP100 Nucleic Acid Amplification Detection Analyzer
• Droplet 48 Automated Microbial Susceptibility Analyzer
• Viral Hepatitis Nucleic Acid Testing Solution
• COVID-19/Influenza A&B Antigen Combo Test Kit
• Novel Coronavirus/Influenza A/B Nucleic Acid Detection Kit
• STD Urine Four-Combination Nucleic Acid Detection Kit
• Cytokine 14-Item Detection Reagent Kit
• I-SPOT.TB Tuberculosis Detection Kit
• NG-Test CARBA5 Carbapenemase Detection Kit
• 14-Cytokine Detection Reagent Kit
• MyCare Antipsychotic Blood Concentration Monitoring Kit
• Fully Automated Nucleic Acid Extraction Purification and PCR Analysis System

Quantifiable outcome

• Detection speed up to 10,400 tests/hour with F-C2000 biochemical analyzer
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature13 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Shanghai Baoshan Central Hospital (Fudan University Affiliated Zhongshan Hospital Wusong Hospital)coreStrategic or Co-development Partner · 25 March 2026Strategic cooperation signing ceremony held for deep integration of clinical laboratory technology innovation and application.双方将聚焦检验医学技术创新、成果转化、人才培养、学科建设等多个维度开展全方位合作。
• Shanghai Ciyuan Rehabilitation HospitalcoreStrategic or Co-development Partner · 24 March 2026Co-construction of standardized demonstration laboratory. Fosun Diagnostics provides standardized laboratory construction system, advanced diagnostic technology, and full-process quality control solutions to upgrade the hospital's testing capabilities.
• Fosun BeilingminorStrategic or Co-development Partner · 1 January 2025Joint construction of mobile cabin laboratory during COVID-19 pandemic for nucleic acid testing capacity expansion.
• Siemens Healthcare Diagnostics Inc.coreTechnology or Integration · 1 May 2022Strategic cooperation for FX Biochemical and Immunological Analysis Line (F-i3000 + XPT). Siemens provides ADVIA Chemistry XPT high-throughput biochemical analyzer combined with Fosun Diagnostics' F-i3000 chemiluminescence immunoassay analyzer for integrated laboratory solutions.
• Saladax (USA)coreTechnology or IntegrationExclusive cooperation for MyCare blood concentration monitoring series. The partnership provides Fosun Diagnostics with exclusive rights to offer 5 antipsychotic drug monitoring tests (clozapine, olanzapine, quetiapine, aripiprazole total, risperidone) for clinical precision medicine.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Maccura Biotechnology: Maccura is a comprehensive Chinese IVD company covering clinical chemistry, immunoassay, molecular diagnostics, and POCT. Their product breadth and channel strategy closely mirror Fosun Diagnostics' six-segment approach to the Chinese hospital market.
• Mindray Bio-Medical Electronics: Shenzhen Mindray is China's largest IVD and medical device company, with comparable full-stack offerings across chemistry, immunoassay, hematology, and microbiology. Like Fosun Diagnostics, Mindray provides both instruments and reagents, but with greater international brand recognition and substantially larger scale.
• Shenzhen New Industries Biomedical Engineering (Snibe): Snibe is a leading Chinese chemiluminescence immunoassay specialist, with MAGLUMI-series analyzers that directly compete with Fosun's F-i3000 and F-i6000. Both companies serve mid-to-large hospital laboratories and follow a similar reagent-pull-through business model.
• KingMed Diagnostics: KingMed is China's largest third-party medical laboratory network, providing diagnostic testing services across pathology, molecular, and specialty testing. Fosun's SBC Biomedlab subsidiary directly competes in this third-party testing segment where Fosun also sells its instruments and reagents.
• Autobio Diagnostics: Autobio is a major Chinese IVD company with strong positions in immunoassay (chemiluminescence) and microbiology, including automated susceptibility analyzers comparable to Fosun's Droplet 48. Both target similar hospital laboratory customers with comparable assay menus.

Emerging players

• Wantai BioPharm: Wantai is a Chinese IVD company with strong positions in infectious disease diagnostics, including HIV, hepatitis, and COVID-19 antigen tests. They represent a direct competitor in molecular diagnostics and home self-testing segments where Fosun has recently expanded.

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is the global IVD leader, with cobas analyzers and Elecsys immunoassays dominating the premium Chinese hospital segment. Fosun's F-Ci series and biochemical-immune assembly lines compete directly with Roche's integrated workflows at Grade 3A hospitals.
• Siemens Healthineers: Siemens Healthineers provides ADVIA Centaur, Atellica, and Dimension platforms that compete head-to-head with Fosun's chemistry and immunoassay analyzers. Fosun's strategic partnership with Siemens on the FX Assembly Line creates a partner/competitor dynamic in the Chinese biochemistry segment.
• Beckman Coulter (Danaher): Beckman Coulter's Access and DxH platforms are widely installed in Chinese hospitals for immunoassay and hematology. Their existing installed base of analyzers compatible with Fosun reagents represents both an opportunity (open reagent platforms) and a competitive threat to Fosun's own analyzers.
• Abbott Diagnostics: Abbott is a global IVD incumbent with ARCHITECT and Alinity platforms in clinical chemistry, immunoassay, and molecular diagnostics. Abbott serves the same large Chinese hospital customer base as Fosun, with stronger international brand presence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/fosun-diagnostics

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fosun Diagnostics